Unknown OBSERVATIONAL NCT04431791

Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer

A Single-center，Observational，Ambispective Cohort Study of Regorafenib Versus Fruquintinib in Metastatic Colorectal Cancer Patients Who Have Progressed After at Least Second Lines of Chemotherapies

Sponsor: Peking University

Conditions Colorectal Cancer

Interventions Fruquintinib Regorafenib

Updated 5 times since 2020 Last updated: Jun 11, 2020 Started: May 25, 2020 Primary completion: Aug 1, 2021 Completion: Feb 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04431791, this observational or N/A phase trial focuses on Colorectal Cancer and remains ongoing. Sponsored by Peking University, it has been updated 5 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jul 2022 — Jul 2024 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Jan 2021 — Jul 2022 [monthly]

Recruiting
Jul 2020 — Jan 2021 [monthly]

Recruiting

First recorded

May 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking University

Data source: Peking University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China